Lead sponsor
Hoffmann-La Roche
25 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
25
Trials led
10
Ongoing
13,099
Total enrollment
1,076
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
5
Phase 2
7
Phase 3
13
Trials by status
Not yet recruiting
2
Recruiting
5
Active, not recruiting
3
Completed
13
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease-Ph 3Completed2,118
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.BMI ≥25Ph 3Completed1,189
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.BMI ≥25Ph 3Completed1,072
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 DiabetesHbA1c 7-10%Ph 3Completed756
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.BMI ≥25Ph 3Completed666
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.BMI ≥25Ph 3Completed373
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination TherapyHbA1c 7-10%Ph 3Terminated370
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity-Ph 2Active, not recruiting352
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.BMI ≥25Ph 3Completed326
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.-Ph 2Completed306
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin MonotherapyBMI 30-50Ph 3Completed305
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesBMI ≥24Ph 3Recruiting300
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesBMI ≥23Ph 2Active, not recruiting240
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.HbA1c 7-9.5%Ph 2Completed133
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes-Ph 3Completed60
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsBMI ≥27Ph 1Recruiting40
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsBMI ≥23Ph 1Not yet recruiting36
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081BMI 18-32Ph 1Completed36